Figure 5.
Difference in c-FLIPS mRNA expression and regulation of its degradation in NSCLC cells. (a) The expression of c-FLIPS in NSCLC cells was analyzed by quantitative real-time polymerase chain reaction (PCR). (b) NSCLC cells were untreated (Untr) or treated with either inhibitor of proteasomal proteolysis MG132 (5 μM, 3 h) or bafilomycin A1 (Baf) (200 nM, 3 h). The expression of c-FLIPS was analyzed by immunoblot. (c) A549 cells were treated with MG132 (5 μM, 3 h) alone or in combination with Ca2+ chelator BAPTA-AM (10 μM, 3 h) or the inhibitors of calmodulin, CMZ (10 μM, 3 h) and FPZ (10 μM, 3 h). The expression of c-FLIPS was analyzed by immunoblot. (d) A549 cells were treated with calmodulin inhibitors and c-FLIPS and procaspase-8 expression were analyzed by immunoblot. Error bars represent S.E. GAPDH, glyceraldehyde 3-phosphate dehydrogenase